206 related articles for article (PubMed ID: 33053175)
41. Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.
Thomas NE; Edmiston SN; Tsai YS; Parker JS; Googe PB; Busam KJ; Scott GA; Zedek DC; Parrish EA; Hao H; Slater NA; Pearlstein MV; Frank JS; Kuan PF; Ollila DW; Conway K
Am J Dermatopathol; 2019 Apr; 41(4):264-272. PubMed ID: 30211730
[TBL] [Abstract][Full Text] [Related]
42. Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer.
Bastian BC
Oncogene; 2003 May; 22(20):3081-6. PubMed ID: 12789284
[TBL] [Abstract][Full Text] [Related]
43. High density of M2-macrophages in acral lentiginous melanoma compared to superficial spreading melanoma.
Zúñiga-Castillo M; Pereira NV; Sotto MN
Histopathology; 2018 Jun; 72(7):1189-1198. PubMed ID: 29415335
[TBL] [Abstract][Full Text] [Related]
44. Acral lentiginous melanoma: histopathological prognostic features of 121 cases.
Phan A; Touzet S; Dalle S; Ronger-Savlé S; Balme B; Thomas L
Br J Dermatol; 2007 Aug; 157(2):311-8. PubMed ID: 17596173
[TBL] [Abstract][Full Text] [Related]
45. TERT gene amplification is associated with poor outcome in acral lentiginous melanoma.
Diaz A; Puig-Butillé JA; Muñoz C; Costa D; Díez A; Garcia-Herrera A; Carrera C; Badenas C; Solé F; Malvehy J; Puig S; Alos L
J Am Acad Dermatol; 2014 Oct; 71(4):839-41. PubMed ID: 25219713
[No Abstract] [Full Text] [Related]
46. Marker Protein Expression Combined With Expression Heterogeneity is a Powerful Indicator of Malignancy in Acral Lentiginous Melanomas.
Cintra Lopes Carapeto F; Neves Comodo A; Germano A; Pereira Guimarães D; Barcelos D; Fernandes M; Landman G
Am J Dermatopathol; 2017 Feb; 39(2):114-120. PubMed ID: 28134728
[TBL] [Abstract][Full Text] [Related]
47. Distinctive dermatoscopic features of acral lentiginous melanoma in situ from plantar melanocytic nevi and their histopathologic correlation.
Kawabata Y; Tamaki K
J Cutan Med Surg; 1998 Apr; 2(4):199-204. PubMed ID: 9558302
[TBL] [Abstract][Full Text] [Related]
48. Treatment and outcomes of melanoma in acral location in Korean patients.
Roh MR; Kim J; Chung KY
Yonsei Med J; 2010 Jul; 51(4):562-8. PubMed ID: 20499423
[TBL] [Abstract][Full Text] [Related]
49. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
Schwaederle M; Krishnamurthy N; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Patel SP; Parker BA; Kurzrock R
Cancer; 2018 Mar; 124(6):1288-1296. PubMed ID: 29211306
[TBL] [Abstract][Full Text] [Related]
50. Telomerase activity in melanocytic lesions: A potential marker of tumor biology.
Rudolph P; Schubert C; Tamm S; Heidorn K; Hauschild A; Michalska I; Majewski S; Krupp G; Jablonska S; Parwaresch R
Am J Pathol; 2000 Apr; 156(4):1425-32. PubMed ID: 10751366
[TBL] [Abstract][Full Text] [Related]
51. MAP Kinase Pathways: Molecular Roads to Primary Acral Lentiginous Melanoma.
Fernandes JD; Hsieh R; de Freitas LA; Brandao MA; Lourenço SV; Sangueza M; Nico MM
Am J Dermatopathol; 2015 Dec; 37(12):892-7. PubMed ID: 26588333
[TBL] [Abstract][Full Text] [Related]
52. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
[TBL] [Abstract][Full Text] [Related]
53. Is the survival rate for acral melanoma actually worse than other cutaneous melanomas?
Lim Y; Lee J; Lee DY
J Dermatol; 2020 Mar; 47(3):251-256. PubMed ID: 31889335
[TBL] [Abstract][Full Text] [Related]
54. Differential clinical significance of alpha(v)Beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes.
Kageshita T; Hamby CV; Hirai S; Kimura T; Ono T; Ferrone S
Int J Cancer; 2000 Mar; 89(2):153-9. PubMed ID: 10754493
[TBL] [Abstract][Full Text] [Related]
55. Expression of soluble adenylyl cyclase in acral melanomas.
Li H; Kim SM; Savkovic V; Jin SA; Choi YD; Yun SJ
Clin Exp Dermatol; 2016 Jun; 41(4):425-9. PubMed ID: 26290224
[TBL] [Abstract][Full Text] [Related]
56. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
[TBL] [Abstract][Full Text] [Related]
57. Decreased expression of hyaluronan synthase 1 and 2 associates with poor prognosis in cutaneous melanoma.
Poukka M; Bykachev A; Siiskonen H; Tyynelä-Korhonen K; Auvinen P; Pasonen-Seppänen S; Sironen R
BMC Cancer; 2016 May; 16():313. PubMed ID: 27184066
[TBL] [Abstract][Full Text] [Related]
58. Acral melanoma: correlating the clinical presentation to the mutational status.
Ravaioli GM; Dika E; Lambertini M; Chessa MA; Fanti PA; Patrizi A
G Ital Dermatol Venereol; 2019 Oct; 154(5):567-572. PubMed ID: 29512974
[TBL] [Abstract][Full Text] [Related]
59. Acral Lentiginous Melanoma: Incidence and Survival in the United States, 2006-2015, an Analysis of the SEER Registry.
Huang K; Fan J; Misra S
J Surg Res; 2020 Jul; 251():329-339. PubMed ID: 32208196
[TBL] [Abstract][Full Text] [Related]
60. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
